[Skip to Navigation]
Sign In

October 2021 - April 2015

Decade

Year

Issue

October 2017, Vol 3, No. 10, Pages 1295-1431

Original Investigation

Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing

Abstract Full Text
open access
JAMA Oncol. 2017;3(10):1327-1334. doi:10.1001/jamaoncol.2017.1040

This study examines 5-year outcomes after cytology showing atypical squamous cells of undetermined significance among women with vs without human papillomavirus testing.

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

Abstract Full Text
free access has audio
JAMA Oncol. 2017;3(10):1335-1342. doi:10.1001/jamaoncol.2017.0589

This population-based study evaluates SEER data on the incidence and prevalence of neuroendocrine tumors over 20 years.

The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population

Abstract Full Text
free access
JAMA Oncol. 2017;3(10):1345-1351. doi:10.1001/jamaoncol.2017.0762

Using study data from SWOG, this study examines the extent to which positive National Cancer Institute–sponsored cancer treatment trials have benefited patients with cancer in the US population.

Trends in Reoperation After Initial Lumpectomy for Breast Cancer: Addressing Overtreatment in Surgical Management

Abstract Full Text
free access has audio
JAMA Oncol. 2017;3(10):1352-1357. doi:10.1001/jamaoncol.2017.0774

This cohort study describes surgeons’ approach to surgical margins for invasive breast cancer, changes in postlumpectomy surgery rates, and final surgical treatment following a 2014 consensus statement endorsing a margin of “no ink on tumor.”

Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer: A Phase 2 Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2017;3(10):1358-1365. doi:10.1001/jamaoncol.2017.0982

This clinical trial examines whether adaptive radiation therapy can target high-dose radiation to the 18F-fludeoxyglucose (FDG)-avid tumor on midtreatment FDG–positron emission tomography with computed tomography to improve local tumor control of locally advanced non–small-cell lung cancer.

Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low-Grade Brain Tumors: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2017;3(10):1368-1376. doi:10.1001/jamaoncol.2017.0997

This phase 3 randomized clinical trial compares neurocognitive and endocrine functional outcomes and survival at 5 years in young patients with residual and/or progressive benign or low-grade brain tumors treated with stereotactic conformal radiotherapy or conventional radiotherapy techniques.

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2017;3(10):1378-1385. doi:10.1001/jamaoncol.2017.1007

This secondary analysis of a randomized clinical trial examines DNA samples and family history of patients with triple-negative breast cancer to determine response to and survival from neoadjuvant treatment.

Association Between Prognosis and Tumor Laterality in Early-Stage Colon Cancer

Abstract Full Text
free access
JAMA Oncol. 2017;3(10):1386-1392. doi:10.1001/jamaoncol.2017.1016

This population-based cohort study explores differences in laterality based on disease characteristics and outcomes in a population-based cohort of early-stage colon cancer.

Trends in Adult Cancer–Related Emergency Department Utilization: An Analysis of Data From the Nationwide Emergency Department Sample

Abstract Full Text
free access online only has audio
JAMA Oncol. 2017;3(10):e172450. doi:10.1001/jamaoncol.2017.2450

This data analysis estimates the proportion of US emergency department visits made by adults with a cancer diagnosis and examines factors related to inpatient admission within this population.

Effect of Modified Vaccinia Ankara–5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial

Abstract Full Text
open access online only
JAMA Oncol. 2017;3(10):e172579. doi:10.1001/jamaoncol.2017.2579

This randomized clinical trial assesses the effect of modified vaccinia Ankara–5T4, metronomic low-dose cyclophosphamide, or a combination of both treatments on antitumor immunity in patients with metastatic colorectal cancer.

Brief Report

Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden

Abstract Full Text
free access
JAMA Oncol. 2017;3(10):1393-1398. doi:10.1001/jamaoncol.2016.3600

This cross-sectional, population-based study evaluates uptake of active surveillance for very-low-risk prostate cancer in Sweden.

Frequency of Thyroid Carcinoma in Brazilian TP53 p.R337H Carriers With Li Fraumeni Syndrome

Abstract Full Text
free access
JAMA Oncol. 2017;3(10):1400-1402. doi:10.1001/jamaoncol.2016.6389

This cohort study determines the frequency of thyroid carcinoma in Brazilians with Li Fraumeni syndrome who are carriers of a founder TP53 p.R337H mutation.

Characterizing 18 Years of the Death With Dignity Act in Oregon

Abstract Full Text
free access
JAMA Oncol. 2017;3(10):1403-1406. doi:10.1001/jamaoncol.2017.0243

This study examines trends in patient utilization of physician-aided dying under the Death With Dignity Act in Oregon between 1998 and 2015.

Research Letter

Association Between Quality of Care for Breast Cancer and Health Insurance Exchange Coverage: An Analysis of Use of Radiation Therapy After Breast-Conserving Surgery

Abstract Full Text
free access
JAMA Oncol. 2017;3(10):1425-1426. doi:10.1001/jamaoncol.2017.1287

This analysis of patients with breast cancer insured through the health insurance marketplace assesses their quality of care by examining patterns of radiation therapy.

Review

Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review

Abstract Full Text
JAMA Oncol. 2017;3(10):1415-1422. doi:10.1001/jamaoncol.2016.5840

This review examines recent developments in tumor visualization for locally advanced, recurrent, and metastatic prostate cancer.

JAMA Oncology Clinical Challenge

New Painful Nodules in a Patient With Multiple Myeloma

Abstract Full Text
JAMA Oncol. 2017;3(10):1423-1424. doi:10.1001/jamaoncol.2017.2112

A woman in her 60s presented with multiple painful cutaneous nodules and a history of IgGκ multiple myeloma. What is your diagnosis?

Viewpoint

Affordability of Cancer Drugs in Sub-Saharan Africa: Effects of Pricing on Needless Loss of Life

Abstract Full Text
JAMA Oncol. 2017;3(10):1301-1302. doi:10.1001/jamaoncol.2017.0479

This Viewpoint cites instances of how the availability of lifesaving cancer drugs in sub-Saharan Africa are increasing overall survival to argue for the increased dissemination of cost-effective or free cancer drugs.

Human-Machine Collaboration in Cancer and Beyond: The Centaur Care Model

Abstract Full Text
JAMA Oncol. 2017;3(10):1303-1304. doi:10.1001/jamaoncol.2016.6413

This Viepoint examines the implementation and possible benefits of human-machine collaboration in treating patients with cancer.

Having a Conversation With a Patient With Incurable Cancer—Just Another Protocol?

Abstract Full Text
JAMA Oncol. 2017;3(10):1305-1306. doi:10.1001/jamaoncol.2016.6776

This Viewpoint examines the need for physicians to approach end-of-life conversations with patients with terminal cancer prognoses with flexibility and an understanding of patient desires and needs.

Deconstructing Clinical Trials—Help From Oncology Value Frameworks

Abstract Full Text
JAMA Oncol. 2017;3(10):1306-1307. doi:10.1001/jamaoncol.2017.1312

This Viewpoint discusses the importance of oncology value frameworks as tools for oncologists in training.

Editorial

Human Papillomavirus Triage of Women With Atypical Squamous Cells of Undetermined Significance—Reduction of Overtreatment Needed

Abstract Full Text
JAMA Oncol. 2017;3(10):1310-1311. doi:10.1001/jamaoncol.2017.1522

Use of Neoadjuvant Platinum—The Ongoing Conundrum

Abstract Full Text
JAMA Oncol. 2017;3(10):1312-1314. doi:10.1001/jamaoncol.2017.1954

Prognostic and Predictive Ability of Tumor Sidedness: Another Vexing Difference Between Localized and Advanced Colon Cancer

Abstract Full Text
JAMA Oncol. 2017;3(10):1314-1315. doi:10.1001/jamaoncol.2017.1905
Invited Commentary

Understanding Neuroendocrine Tumors—A NET Gain

Abstract Full Text
JAMA Oncol. 2017;3(10):1343-1344. doi:10.1001/jamaoncol.2017.0575

Dose Escalation Optimization in Patients With Locally Advanced Non–Small-Cell Lung Cancer: The Right Dose, in the Right Location, to the Right Patient, at the Right Time

Abstract Full Text
JAMA Oncol. 2017;3(10):1365-1367. doi:10.1001/jamaoncol.2017.1344

Conventional Radiation Therapy Compared With Stereotactic Conformal Therapy—A Rare and Laudable Randomized Trial

Abstract Full Text
JAMA Oncol. 2017;3(10):1376-1377. doi:10.1001/jamaoncol.2017.1552

Active Surveillance for Low-Risk Prostate Cancer—An Evolving International Standard of Care

Abstract Full Text
JAMA Oncol. 2017;3(10):1398-1399. doi:10.1001/jamaoncol.2016.3179
Cancer Care Chronicles

Bath

Abstract Full Text
JAMA Oncol. 2017;3(10):1308. doi:10.1001/jamaoncol.2016.6132

Bourbon

Abstract Full Text
JAMA Oncol. 2017;3(10):1309. doi:10.1001/jamaoncol.2017.1067
Comment & Response

Risk of Primary Tumor Sidedness as a Criterion for Screening, Diagnostic Colonoscopy, and Surveillance Intervals

Abstract Full Text
JAMA Oncol. 2017;3(10):1426-1427. doi:10.1001/jamaoncol.2017.1504

When Somatic Mutations Are Associated With a Higher Aggressive Behavior—A Story of Announced Evidence

Abstract Full Text
JAMA Oncol. 2017;3(10):1427-1428. doi:10.1001/jamaoncol.2017.1510

Risk of Primary Tumor Sidedness as a Criterion for Screening, Diagnostic Colonoscopy, and Surveillance Intervals—Reply

Abstract Full Text
JAMA Oncol. 2017;3(10):1427. doi:10.1001/jamaoncol.2017.1516

When Somatic Mutations Are Associated With a Higher Aggressive Behavior—A Story of Announced Evidence—Reply

Abstract Full Text
JAMA Oncol. 2017;3(10):1428-1429. doi:10.1001/jamaoncol.2017.1513

Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden

Abstract Full Text
JAMA Oncol. 2017;3(10):1429. doi:10.1001/jamaoncol.2016.7092

Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden—Reply

Abstract Full Text
JAMA Oncol. 2017;3(10):1429-1430. doi:10.1001/jamaoncol.2017.1747

Demonstrating Noninferiority of Accelerated Radiotherapy With Panitumumab vs Standard Radiotherapy With Cisplatin in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma

Abstract Full Text
JAMA Oncol. 2017;3(10):1430-1431. doi:10.1001/jamaoncol.2017.0737

Demonstrating Noninferiority of Accelerated Radiotherapy With Panitumumab vs Standard Radiotherapy With Cisplatin in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma—Reply

Abstract Full Text
JAMA Oncol. 2017;3(10):1431. doi:10.1001/jamaoncol.2017.2023
Correction

Error in Patient Data in Abstract and Text

Abstract Full Text
free access
JAMA Oncol. 2017;3(10):1431. doi:10.1001/jamaoncol.2017.1330

Missing Source Credit for Figure and Table

Abstract Full Text
free access
JAMA Oncol. 2017;3(10):1431. doi:10.1001/jamaoncol.2017.1915

Errors in Tables

Abstract Full Text
free access
JAMA Oncol. 2017;3(10):1431. doi:10.1001/jamaoncol.2017.2897
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2017;3(10):1297. doi:10.1001/jamaoncol.2016.4464
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2017;3(10):1295. doi:10.1001/jamaoncol.2016.4463
×